Comprehensive Clinical Guide: Lattice Corneal Dystrophy Type I (LCD I)

1. Introduction and Overview

Lattice Corneal Dystrophy Type I (LCD I), historically known as Biber-Haab-Dimmer dystrophy, is a rare, autosomal dominant, bilateral, progressive disorder of the corneal stroma. Classified as a TGFBI-associated corneal dystrophy, it is characterized by the accumulation of amyloid deposits within the central corneal stroma.

Clinically, it presents as a branching network of refractile, lattice-like opacities that gradually coalesce, leading to significant visual impairment, recurrent corneal erosions, and eventual stromal haze. As an expert clinical guide, this document serves to delineate the pathophysiology, diagnostic criteria, and management paradigms for practitioners managing patients with this sight-threatening condition.

2. Etiology and Pathophysiology

Genetic Foundation

LCD I is caused by mutations in the TGFBI (Transforming Growth Factor Beta Induced) gene, located on chromosome 5q31. The most prevalent mutation associated with the classic Type I phenotype is the R124C substitution.

Molecular Mechanism

The TGFBI gene encodes for the protein keratoepithelin, which is normally expressed in the corneal epithelium and stroma. In LCD I, the mutated protein is incorrectly folded and susceptible to proteolytic cleavage. This leads to the extracellular deposition of amyloid fibrils. These fibrils stain positively with Congo Red and exhibit apple-green birefringence under polarized light, confirming their amyloid nature.

Histopathological Progression

1. Initial Phase: Amyloid deposits manifest initially in the subepithelial space and the anterior stroma.
2. Intermediate Phase: Deposits expand into the middle stroma, forming a characteristic "lattice" pattern.
3. Advanced Phase: Deposits become confluent, causing significant stromal thickening and potential damage to the Bowman’s layer.

3. Clinical Presentation and Staging

Standard Presentation

Patients typically present in the first or second decade of life. The hallmark symptom is recurrent corneal erosion (RCE), often manifesting as sharp, stabbing ocular pain upon awakening. This is followed by a progressive decline in visual acuity due to central corneal opacity and irregular astigmatism.

Clinical Staging/Grading Table

4. Diagnostic Evaluation

Key Diagnostic Tests

• Slit-Lamp Biomicroscopy: The gold standard for initial diagnosis. Utilization of retro-illumination is critical to visualize the fine, white, refractive lattice lines.
• In Vivo Confocal Microscopy (IVCM): A non-invasive diagnostic tool that reveals hyper-reflective, filamentous, and globular deposits in the subepithelial and stromal layers, often showing a "meshwork" pattern.
• Anterior Segment OCT (AS-OCT): Useful for quantifying the depth of deposits and assessing the integrity of the Bowman’s layer.
• Genetic Testing: Definitive confirmation via PCR-based analysis of the TGFBI gene to identify specific mutations.

Differential Diagnosis

Clinicians must differentiate LCD I from other stromal dystrophies:
* Granular Corneal Dystrophy (GCD): Presents with crumb-like, white opacities; lacks the lattice-like branching pattern.
* Avellino Dystrophy (GCD Type II): A hybrid of lattice and granular dystrophy; often displays both amyloid and hyaline deposits.
* Gelatinous Drop-Like Corneal Dystrophy (GDLD): Presents with subepithelial mulberry-like nodules rather than lattice lines.

5. Management and Therapeutic Paradigms

Conservative Management

For mild cases, the focus is on mitigating recurrent corneal erosions:
* Hypertonic saline drops/ointments: To reduce stromal edema and improve epithelial adhesion.
* Lubricating, preservative-free artificial tears: Frequency as needed.
* Therapeutic bandage contact lenses: For persistent RCEs or patient comfort.

Surgical Intervention

When visual acuity drops below acceptable levels (typically 20/40 or worse) or RCEs become unmanageable:
1. Phototherapeutic Keratectomy (PTK): An excimer laser procedure used to ablate superficial amyloid deposits. High recurrence rates are common, but it can delay the need for transplantation.
2. Deep Anterior Lamellar Keratoplasty (DALK): The preferred surgical approach. It replaces the diseased stroma while preserving the patient’s healthy endothelium, significantly reducing the risk of graft rejection.
3. Penetrating Keratoplasty (PKP): Reserved for cases where deep stromal involvement or endothelial failure is present.

6. Risks, Side Effects, and Contraindications

Surgical Risks

• Recurrence: Lattice dystrophy is notorious for recurring in the graft tissue, even after successful keratoplasty. This is due to the systemic nature of the protein expression, though the process is much slower in the donor tissue.
• Graft Rejection: Post-operative monitoring for inflammation is critical.
• Refractive Shift: Significant astigmatism is common post-surgery, often requiring specialty contact lenses.

Contraindications

• Avoid LASIK/PRK for Refractive Correction: Performing LASIK on a cornea with known TGFBI mutations is contraindicated as it can accelerate the progression of the dystrophy and lead to severe, unpredictable stromal haze.

7. Prognosis

The long-term prognosis for LCD I is guarded but generally favorable with modern surgical techniques. While the condition is progressive and recurrent, most patients achieve functional vision through DALK. Patients require lifelong follow-up with a corneal specialist to monitor for recurrent deposits and potential graft failure.

8. Frequently Asked Questions (FAQ)

1. Is Lattice Corneal Dystrophy Type I curable?
There is no permanent cure. While surgeries like DALK can restore vision, the condition is genetic and may recur in the donor graft over several years or decades.

2. At what age does the condition typically begin?
Symptoms usually appear in childhood or adolescence, often starting with corneal erosions.

3. Is this condition related to systemic amyloidosis?
No. LCD I is a localized corneal disease. It is not associated with systemic amyloidosis, which affects internal organs.

4. Can I wear contact lenses with LCD I?
Many patients with early-stage LCD I can wear contact lenses. However, as the surface becomes irregular, rigid gas-permeable or scleral lenses may be required to achieve clear vision.

5. Is genetic testing necessary for my family?
Yes, because the condition is autosomal dominant, first-degree relatives should undergo an eye examination and potential genetic counseling.

6. What is the most common symptom of LCD I?
Recurrent corneal erosion (RCE), characterized by sharp, sudden pain, tearing, and photophobia, is the most common early symptom.

7. Does smoking affect the progression of LCD I?
While not directly linked to the genetic mutation, general ocular health is improved by smoking cessation, as it reduces inflammation and improves corneal healing capacity.

8. Is LASIK an option to fix my vision if I have LCD I?
Absolutely not. Laser refractive surgery can trigger an aggressive progression of the dystrophy and is strictly contraindicated.

9. How often should I see my ophthalmologist?
Patients should maintain a biannual or annual follow-up schedule, or more frequently if they experience a spike in erosions or a decline in vision.

10. What is the difference between Type I and Type II Lattice Dystrophy?
Type I is strictly corneal. Type II (often associated with Meretoja syndrome) is a systemic condition involving lattice corneal dystrophy combined with cranial nerve palsies and skin laxity.

9. Conclusion

Lattice Corneal Dystrophy Type I represents a complex challenge in corneal practice. By understanding the underlying genetic basis (R124C mutation) and the progressive nature of the amyloid deposition, clinicians can better manage patient expectations and optimize surgical outcomes. Early recognition of recurrent erosions and timely intervention via lamellar transplantation remain the cornerstones of preserving ocular health and quality of life for these patients.